Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Differential protein expression and basal lamina remodeling in human heart failure.

Kim EH, Galchev VI, Kim JY, Misek SA, Stevenson TK, Campbell MD, Pagani FD, Day SM, Johnson TC, Washburn JG, Vikstrom KL, Michele DE, Misek DE, Westfall MV.

Proteomics Clin Appl. 2016 May;10(5):585-96. doi: 10.1002/prca.201500099. Epub 2016 Jan 25.

2.

ATDC (Ataxia Telangiectasia Group D Complementing) Promotes Radioresistance through an Interaction with the RNF8 Ubiquitin Ligase.

Yang H, Palmbos PL, Wang L, Kim EH, Ney GM, Liu C, Prasad J, Misek DE, Yu X, Ljungman M, Simeone DM.

J Biol Chem. 2015 Nov 6;290(45):27146-57. doi: 10.1074/jbc.M115.665489. Epub 2015 Sep 17.

3.

Proteomics-based disease biomarkers.

Misek DE, Kondo T, Duncan MW.

Int J Proteomics. 2011;2011:894618. doi: 10.1155/2011/894618. Epub 2011 Oct 30. No abstract available.

4.

Comprehensive proteomic profiling of aldehyde dehydrogenases in lung adenocarcinoma cell lines.

Zhang Q, Taguchi A, Schliekelman M, Wong CH, Chin A, Kuick R, Misek DE, Hanash S.

Int J Proteomics. 2011;2011:145010. doi: 10.1155/2011/145010. Epub 2011 Oct 29.

5.

Glycoproteomics-based identification of cancer biomarkers.

Kim EH, Misek DE.

Int J Proteomics. 2011;2011:601937. doi: 10.1155/2011/601937. Epub 2011 Sep 28.

6.

Protein biomarkers for the early detection of breast cancer.

Misek DE, Kim EH.

Int J Proteomics. 2011;2011:343582. doi: 10.1155/2011/343582. Epub 2011 Aug 11.

7.

Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway.

Vilar E, Mukherjee B, Kuick R, Raskin L, Misek DE, Taylor JM, Giordano TJ, Hanash SM, Fearon ER, Rennert G, Gruber SB.

Clin Cancer Res. 2009 Apr 15;15(8):2829-39. doi: 10.1158/1078-0432.CCR-08-2432. Epub 2009 Apr 7.

8.

Comparative proteomic study of two closely related ovarian endometrioid adenocarcinoma cell lines using cIEF fractionation and pathway analysis.

Dai L, Li C, Shedden KA, Misek DE, Lubman DM.

Electrophoresis. 2009 Apr;30(7):1119-31. doi: 10.1002/elps.200800505.

9.

Differential protein mapping of ovarian serous adenocarcinomas: identification of potential markers for distinct tumor stage.

Wang Y, Wu R, Cho KR, Thomas DG, Gossner G, Liu JR, Giordano TJ, Shedden KA, Misek DE, Lubman DM.

J Proteome Res. 2009 Mar;8(3):1452-63. doi: 10.1021/pr800820z.

10.

A biomarker panel for acute graft-versus-host disease.

Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, Misek DE, Cooke KR, Kitko CL, Weyand A, Bickley D, Jones D, Whitfield J, Reddy P, Levine JE, Hanash SM, Ferrara JL.

Blood. 2009 Jan 8;113(2):273-8. doi: 10.1182/blood-2008-07-167098. Epub 2008 Oct 2.

11.

Identification of a Specific Vimentin Isoform That Induces an Antibody Response in Pancreatic Cancer.

Hong SH, Misek DE, Wang H, Puravs E, Hinderer R, Giordano TJ, Greenson JK, Brenner DE, Simeone DM, Logsdon CD, Hanash SM.

Biomark Insights. 2006;1:175-183.

12.

Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.

Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma, Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan VE, Meyerson M, Kuick R, Dobbin KK, Lively T, Jacobson JW, Beer DG.

Nat Med. 2008 Aug;14(8):822-7. doi: 10.1038/nm.1790. Epub 2008 Jul 20.

13.

Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas.

Kim H, Wu R, Cho KR, Thomas DG, Gossner G, Liu JR, Giordano TJ, Shedden KA, Misek DE, Lubman DM.

Proteomics Clin Appl. 2008 Mar 7;2(4):571-584.

14.

Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot.

Qiu Y, Patwa TH, Xu L, Shedden K, Misek DE, Tuck M, Jin G, Ruffin MT, Turgeon DK, Synal S, Bresalier R, Marcon N, Brenner DE, Lubman DM.

J Proteome Res. 2008 Apr;7(4):1693-703. doi: 10.1021/pr700706s. Epub 2008 Feb 27.

15.

Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer.

Pereira-Faca SR, Kuick R, Puravs E, Zhang Q, Krasnoselsky AL, Phanstiel D, Qiu J, Misek DE, Hinderer R, Tammemagi M, Landi MT, Caporaso N, Pfeiffer R, Edelstein C, Goodman G, Barnett M, Thornquist M, Brenner D, Hanash SM.

Cancer Res. 2007 Dec 15;67(24):12000-6.

16.

Early detection and biomarkers in pancreatic cancer.

Misek DE, Patwa TH, Lubman DM, Simeone DM.

J Natl Compr Canc Netw. 2007 Nov;5(10):1034-41. Review.

PMID:
18053427
17.

Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response.

Madoz-Gúrpide J, Kuick R, Wang H, Misek DE, Hanash SM.

Mol Cell Proteomics. 2008 Feb;7(2):268-81. Epub 2007 Oct 4.

18.
19.

Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera.

Zhao J, Patwa TH, Qiu W, Shedden K, Hinderer R, Misek DE, Anderson MA, Simeone DM, Lubman DM.

J Proteome Res. 2007 May;6(5):1864-74. Epub 2007 Apr 12.

PMID:
17428079
20.

Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.

Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, Cho KR.

Cancer Cell. 2007 Apr;11(4):321-33.

21.

Discovery of cancer biomarkers through the use of mouse models.

Kuick R, Misek DE, Monsma DJ, Webb CP, Wang H, Peterson KJ, Pisano M, Omenn GS, Hanash SM.

Cancer Lett. 2007 Apr 28;249(1):40-8. Epub 2007 Feb 22. Review.

PMID:
17320282
22.

Comparative proteomics analysis of Barrett metaplasia and esophageal adenocarcinoma using two-dimensional liquid mass mapping.

Zhao J, Chang AC, Li C, Shedden KA, Thomas DG, Misek DE, Manoharan AP, Giordano TJ, Beer DG, Lubman DM.

Mol Cell Proteomics. 2007 Jun;6(6):987-99. Epub 2006 Jul 8.

23.

Long-term ethanol consumption alters pancreatic gene expression in rats: a possible connection to pancreatic injury.

Kubisch CH, Gukovsky I, Lugea A, Pandol SJ, Kuick R, Misek DE, Hanash SM, Logsdon CD.

Pancreas. 2006 Jul;33(1):68-76.

PMID:
16804415
24.

Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation.

Giordano TJ, Au AY, Kuick R, Thomas DG, Rhodes DR, Wilhelm KG Jr, Vinco M, Misek DE, Sanders D, Zhu Z, Ciampi R, Hanash S, Chinnaiyan A, Clifton-Bligh RJ, Robinson BG, Nikiforov YE, Koenig RJ.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1983-93.

25.

Podocyte hypertrophy, "adaptation," and "decompensation" associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction.

Wiggins JE, Goyal M, Sanden SK, Wharram BL, Shedden KA, Misek DE, Kuick RD, Wiggins RC.

J Am Soc Nephrol. 2005 Oct;16(10):2953-66. Epub 2005 Aug 24.

26.

Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis.

Gao WM, Kuick R, Orchekowski RP, Misek DE, Qiu J, Greenberg AK, Rom WN, Brenner DE, Omenn GS, Haab BB, Hanash SM.

BMC Cancer. 2005 Aug 23;5:110.

27.

A wide range of protein isoforms in serum and plasma uncovered by a quantitative intact protein analysis system.

Misek DE, Kuick R, Wang H, Galchev V, Deng B, Zhao R, Tra J, Pisano MR, Amunugama R, Allen D, Walker AK, Strahler JR, Andrews P, Omenn GS, Hanash SM.

Proteomics. 2005 Aug;5(13):3343-52.

PMID:
16047307
28.

Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis.

Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, Gauger P, Doherty G, Thompson NW, Hanash S, Koenig RJ, Nikiforov YE.

Oncogene. 2005 Oct 6;24(44):6646-56.

PMID:
16007166
29.

CDX2 polymorphisms, RNA expression, and risk of colorectal cancer.

Rozek LS, Lipkin SM, Fearon ER, Hanash S, Giordano TJ, Greenson JK, Kuick R, Misek DE, Taylor JM, Douglas JA, Rennert G, Gruber SB.

Cancer Res. 2005 Jul 1;65(13):5488-92.

30.
31.

Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formation.

Creighton CJ, Bromberg-White JL, Misek DE, Monsma DJ, Brichory F, Kuick R, Giordano TJ, Gao W, Omenn GS, Webb CP, Hanash SM.

Mol Cancer Res. 2005 Mar;3(3):119-29.

32.

Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.

Shedden KA, Kshirsagar MP, Schwartz DR, Wu R, Yu H, Misek DE, Hanash S, Katabuchi H, Ellenson LH, Fearon ER, Cho KR.

Clin Cancer Res. 2005 Mar 15;11(6):2123-31.

33.

Intact-protein-based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids.

Wang H, Clouthier SG, Galchev V, Misek DE, Duffner U, Min CK, Zhao R, Tra J, Omenn GS, Ferrara JL, Hanash SM.

Mol Cell Proteomics. 2005 May;4(5):618-25. Epub 2005 Feb 9.

34.

Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays.

Dobbin KK, Beer DG, Meyerson M, Yeatman TJ, Gerald WL, Jacobson JW, Conley B, Buetow KH, Heiskanen M, Simon RM, Minna JD, Girard L, Misek DE, Taylor JM, Hanash S, Naoki K, Hayes DN, Ladd-Acosta C, Enkemann SA, Viale A, Giordano TJ.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):565-72.

35.

Application of proteomic technologies to tumor analysis.

Misek DE, Imafuku Y, Hanash SM.

Pharmacogenomics. 2004 Dec;5(8):1129-37. Review.

PMID:
15584879
36.

Oligonucleotide-directed microarray gene profiling of pancreatic adenocarcinoma.

Misek DE, Kuick R, Hanash SM, Logsdon CD.

Methods Mol Med. 2005;103:175-87.

PMID:
15542906
37.

Hepatitis C virus NS5A-regulated gene expression and signaling revealed via microarray and comparative promoter analyses.

Girard S, Vossman E, Misek DE, Podevin P, Hanash S, Bréchot C, Beretta L.

Hepatology. 2004 Sep;40(3):708-18.

38.

An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer.

Hong SH, Misek DE, Wang H, Puravs E, Giordano TJ, Greenson JK, Brenner DE, Simeone DM, Logsdon CD, Hanash SM.

Cancer Res. 2004 Aug 1;64(15):5504-10.

39.

Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens.

Qiu J, Madoz-Gurpide J, Misek DE, Kuick R, Brenner DE, Michailidis G, Haab BB, Omenn GS, Hanash S.

J Proteome Res. 2004 Mar-Apr;3(2):261-7. Review.

PMID:
15113102
40.

Genomic and proteomic analyses of vascular endothelial growth factor and insulin-like growth factor-binding protein 3 in lung adenocarcinomas.

Gharib TG, Chen G, Huang CC, Misek DE, Iannettoni MD, Hanash SM, Orringer MB, Beer DG.

Clin Lung Cancer. 2004 Mar;5(5):307-12.

PMID:
15086970
41.

Molecular profiling and the identification of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma.

Schmalbach CE, Chepeha DB, Giordano TJ, Rubin MA, Teknos TN, Bradford CR, Wolf GT, Kuick R, Misek DE, Trask DK, Hanash S.

Arch Otolaryngol Head Neck Surg. 2004 Mar;130(3):295-302.

PMID:
15023835
42.

Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas.

Chen G, Wang H, Miller CT, Thomas DG, Gharib TG, Misek DE, Giordano TJ, Orringer MB, Hanash SM, Beer DG.

J Pathol. 2004 Mar;202(3):321-9.

43.

The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis.

Cuezva JM, Chen G, Alonso AM, Isidoro A, Misek DE, Hanash SM, Beer DG.

Carcinogenesis. 2004 Jul;25(7):1157-63. Epub 2004 Feb 12.

PMID:
14963017
44.

Aging is associated with increased T-cell chemokine expression in C57BL/6 mice.

Chen J, Mo R, Lescure PA, Misek DE, Hanash S, Rochford R, Hobbs M, Yung RL.

J Gerontol A Biol Sci Med Sci. 2003 Nov;58(11):975-83.

PMID:
14630877
45.

Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3.

Nam MJ, Madoz-Gurpide J, Wang H, Lescure P, Schmalbach CE, Zhao R, Misek DE, Kuick R, Brenner DE, Hanash SM.

Proteomics. 2003 Nov;3(11):2108-15.

PMID:
14595809
46.

Accurate molecular classification of human cancers based on gene expression using a simple classifier with a pathological tree-based framework.

Shedden KA, Taylor JM, Giordano TJ, Kuick R, Misek DE, Rennert G, Schwartz DR, Gruber SB, Logsdon C, Simeone D, Kardia SL, Greenson JK, Cho KR, Beer DG, Fearon ER, Hanash S.

Am J Pathol. 2003 Nov;163(5):1985-95.

47.

Protein profiles associated with survival in lung adenocarcinoma.

Chen G, Gharib TG, Wang H, Huang CC, Kuick R, Thomas DG, Shedden KA, Misek DE, Taylor JM, Giordano TJ, Kardia SL, Iannettoni MD, Yee J, Hogg PJ, Orringer MB, Hanash SM, Beer DG.

Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13537-42. Epub 2003 Oct 22.

48.

Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas.

Miller CT, Chen G, Gharib TG, Wang H, Thomas DG, Misek DE, Giordano TJ, Yee J, Orringer MB, Hanash SM, Beer DG.

Oncogene. 2003 Sep 11;22(39):7950-7.

PMID:
12970743
49.
50.

Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction.

van den Boom J, Wolter M, Kuick R, Misek DE, Youkilis AS, Wechsler DS, Sommer C, Reifenberger G, Hanash SM.

Am J Pathol. 2003 Sep;163(3):1033-43.

Supplemental Content

Loading ...
Support Center